tetano
Editor, Senior Moderator
Pharmacotherapy. 2020 Apr 13. doi: 10.1002/phar.2403. [Epub ahead of print]
Delayed Initiation of Remdesivir in a COVID-19 Positive Patient.
Hillaker E[SUP]1[/SUP], Belfer JJ[SUP]2[/SUP], Bondici A[SUP]3[/SUP], Murad H[SUP]4[/SUP], Dumkow LE[SUP]2[/SUP].
Author information
Abstract
A case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical ICU of a community teaching hospital is presented. A previously healthy 40 year-old male was admitted to the hospital three days after the onset of coronavirus disease 2019 (COVID-19) symptoms, including dry cough, fever, and shortness of breath progressing to intubation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID-19 PCR result. Supportive measures, in addition to a 5-day course of hydroxychloroquine, were maintained until remdesivir could be supplied on day 9 of hospitalization, 13 days after symptom onset. Sixty hours after initiating remdesivir, the patient was successfully extubated and was able to transition to room air within 24 hours of extubation. Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals utilized for different disease states, such as oseltamivir, which are most effective when started as soon as possible following symptom onset. Urgent action is needed by regulatory agencies to work with drug manufacturers to expedite the study and approval of investigational agents targeting SARS-CoV-2 as well as to meet manufacturing demands.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; SARS-CoV-2; coronavirus; pneumonia; remdesivir; viral pneumonia
PMID:32281114DOI:10.1002/phar.2403
Delayed Initiation of Remdesivir in a COVID-19 Positive Patient.
Hillaker E[SUP]1[/SUP], Belfer JJ[SUP]2[/SUP], Bondici A[SUP]3[/SUP], Murad H[SUP]4[/SUP], Dumkow LE[SUP]2[/SUP].
Author information
Abstract
A case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical ICU of a community teaching hospital is presented. A previously healthy 40 year-old male was admitted to the hospital three days after the onset of coronavirus disease 2019 (COVID-19) symptoms, including dry cough, fever, and shortness of breath progressing to intubation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID-19 PCR result. Supportive measures, in addition to a 5-day course of hydroxychloroquine, were maintained until remdesivir could be supplied on day 9 of hospitalization, 13 days after symptom onset. Sixty hours after initiating remdesivir, the patient was successfully extubated and was able to transition to room air within 24 hours of extubation. Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals utilized for different disease states, such as oseltamivir, which are most effective when started as soon as possible following symptom onset. Urgent action is needed by regulatory agencies to work with drug manufacturers to expedite the study and approval of investigational agents targeting SARS-CoV-2 as well as to meet manufacturing demands.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; SARS-CoV-2; coronavirus; pneumonia; remdesivir; viral pneumonia
PMID:32281114DOI:10.1002/phar.2403